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farction. Circulation. 2002;105:726-31.Cardiopulmonary bypass strategy with low-dose heparin and
nafamostat mesilate in cardiac surgery: A safe option for patients
with acute strokeNaoto Morimoto, MD, PhD, Soichiro Henmi, MD, Masato Yoshida, MD, and Nobuhiko Mukohara, MD,
Himeji, JapanPatients undergoing open cardiac surgical procedures with
a history of acute stroke pose a difficult management prob-
lem. There is always the risk that cardiopulmonary bypass
(CPB) and heparinization may induce intracranial hemor-
rhage. A multicenter study suggests that open cardiac surgi-
cal procedures can be performed safely 4 weeks after
stroke1; however, some patients with acute cardiogenic
stroke occasionally require emergency surgery because of
uncontrollable heart failure or ongoing thromboembolism.
Heparinized CPB with low systemic heparinization is
among the therapeutic options when operating on patients
with the risk of intracranial hemorrhage; however, low sys-
temic heparinization could allow clot formation.2 Nafamo-
stat mesilate (6-amino-2-naphthyl p-guanidinobenzoate
dimethanesulfonate, currently available in Japan and Korea)
is a serine protease inhibitor that has such activities as anti-
coagulant effect (by inhibiting coagulation factors, XIIa, Xa,
and VIIa, along with thrombin), antifibrinolytic activities
(by inhibiting tissue-type and urokinase plasminogen acti-
vators), and antiplatelet actions.3,4 Because of a short half-
life of 8 minutes, it has recently been used mainly as an
anticoagulant for hemodialysis5 and extracorporeal mem-
brane oxygenation6 in patients with bleeding tendencies.
Nafamostat mesilate has been widely used in Japan as an al-
ternative anticoagulant agent during hemodialysis, and its
in vivo effect as an anticoagulant has been established.3
In this study, we report a successful CPB strategy
with low-dose heparin and nafamostat mesilate as ananticoagulant to reduce the dosage of heparin for patients
with acute stroke.MATERIALS AND METHODS
With approval of the institutional reviewboard and patient informed con-
sent, patients who underwent cardiac surgery with CPB with low-dose hep-
arin and nafamostat mesilate were included. From November 2007 and
January 2010, we had 17 patients with courses complicated by acute stroke.
The patient characteristics are listed in Table 1. Acute stroke was detected
by diffusion-weightedmagnetic resonance images in 16 cases, and 1 patient
had subarachnoid hemorrhage from a ruptured mycotic aneurysm. Of these
patients, 14 patients had a diagnosis of active infective endocarditis accord-
ing to modified Duke criteria. The remaining 3 patients had acute pulmo-
nary embolism with atrial septal defect, left ventricular thrombus, or left
atrial myxoma. Mean age was 63.9  16.7 years. Seven patients (41.2%)
were female. The indication for the operation was uncontrolled sepsis in
7 patients, uncontrollable heart failure in 5 patients, and ongoing thrombo-
embolism in 5 patients. Themean interval from the onset of stroke to surgery
was 2.9  0.4 days. All operations were performed as routine procedures
except for the CPB anticoagulationmanagement. Brain computed tomogra-
phy was performed within 3 days after the surgery in all cases.
Anticoagulation Protocol During CPB
Anticoagulation during CPB was managed as follows: before connec-
tion of the extracorporeal circuit, 0.8 mg/kg of nafamostat mesilate and
50 IU/kg of heparin (our normal dosage for CPB is 300 IU/kg) were admin-
istered to obtain a diatomaceous earth (Celite; World Minerals Inc, Santa
Barbara, Calif) activated clotting time (DEACT, measured with ACTII;
Medtronic BloodManagement, Parker, Colo) over 250 seconds. If DEACT
did not rise above 250 seconds, a 200-IU dose of heparin was administered.
CPB was composed of a roller pump (Mera HAS; Senko Medical
Instrument Mfg Co Ltd, Tokyo, Japan), a silicon- and heparin-coated hol-
low-fiber polypropylene oxygenator (Mera NHP Excelung Prime HPO-
23WH-C; Senko) and a heparin-coated bypass circuit (Mera Exceline-S,
0.5-inch; Senko). After connection to the pump circuit, nafamostat mesilate
and heparin were continuously infused through the venous line of the pump
circuit at 0.8/mg/(kg $ h) and 25 IU/(kg $ h), respectively. DEACT, for
which blood samples were taken from the venous circuit line every 10 min-
utes, was maintained between 400 and 600 seconds during CPB. If DEACT
exceeded 600 seconds, the continuous infusion of heparin was reduced. An
additional bolus injection of 100 IU of heparinwas administratedwhenDE-
ACT fell below 400 seconds. Furthermore, kaolin-measured ACT (KACT,
measured with Hemochron401; International Technidyne Corp, Edison,
NJ) was monitored simultaneously. KACT reflects the heparin activity inery c September 2012
TABLE 1. Summary of data
Case
no.
Age
(y) Sex Diagnosis Neurologic history Operation and time to surgery
ECC time
(min)
Blood loss
(g) Outcome
1 54 M NVE (mitral) Right parietal hemorrhagic infarct MVR (0 d) 138 540 Alive
2 63 M NVE (mitral) Multiple infarcts MVR (4 d) 210 280 Alive
3 75 M NVE (aortic) Multiple infarcts AVR (0 d) 106 580 Alive
4 62 F NVE (mitral) Multiple infarcts MVR (14 d) 106 170 Alive
5 84 F NVE (aortic), AP SAH AVR, CABG (28 d) 241 830 Alive
6 78 M NVE (aortic/mitral) Right parietal infarct AVR, MVR (17 d) 257 330 Alive
7 38 M NVE (aortic/mitral) Multiple infarcts MVR (11 d) 176 360 Alive
8 64 F NVE (mitral) Multiple infarcts MVR, CABG (1 d) 155 560 Alive
9 69 M NVE (aortic/mitral) Right frontal infarct AVR, MVR (1 d) 313 670 Alive
10 81 F NVE (mitral) Left occipital infarct MVR (3 d) 157 200 Alive
11 70 M NVE (mitral) Multiple infarcts MVR (3 d) 198 340 Alive
12 67 M NVE (aortic) Multiple infarcts AVR (3 d) 103 600 Alive
13 22 M NVE (mitral) Multiple infarcts MVR (1 d) 181 290 Alive
14 79 F PVE (aortic) Multiple infarcts AVR (3 d) 151 450 Alive
15 79 F Acute PTE, ASD Right frontal infarct ASD closure, PE (3 d) 115 1780 Alive
16 45 M LV thrombus, AMI Left frontal infarct CABG, removal of thrombus (2 d) 58 210 Alive
17 57 F LA myxoma Right lower occipital infarct Resection of LA myxoma (3 d) 57 100 Alive
ECC, Extracorporeal circulation; M,male; NVE, native valve endocarditis;MVR, mitral valve replacement; AVR, aortic valve replacement; F, female; AP, angina pectoris; SAH,
subarachnoid hemorrhage; CABG, coronary artery bypass grafting; PVE, prosthetic valve endocarditis; PTE, pulmonary thromboembolism; ASD, atrial septal defect; PE,
pulmonary embolectomy; LV, left ventricular; AMI, acute myocardial infarction; LA, left atrial.
Surgical Techniquesthe blood under the combined use of nafamostatmesilate because kaolin ab-
sorbs nafamostat mesilate, thus minimizing its effect on KACT.7 The value
of KACT was kept between 200 and 300 seconds. If the KACT reading
fell below 200 seconds, a 200-IU dose of heparin was added.
The pump flow was set at 2.4 to 2.6 L/(min $ m2). All patients were
cooled tomild hypothermia (33C–34C). Targetmean systemic blood pres-
sure was 60 mm Hg. Cerebral oxygenation was monitored with a near-
infrared oxygen monitor (INVOS 4100; Somanetics Corporation, Troy,
Mich). The pump flow was adjusted to keep the cerebral oxygenation satu-
rationvalue the same as at the anesthetic induction. Afterweaning fromCPB
and decannulation, residual heparin was reversed with protamine sulfate.
Dosage of protamine sulfate was 1 mg for every 100 IU of initial heparin.FIGURE 1. Diatomaceous earth– and kaolin-derived clotting time (ACT) value
for diatomaceous earth–derived activated clotting time.
The Journal of Thoracic and CaRESULTS
Mean dosages of nafamostat mesilate and heparin were
164  64 mg and 704  314 IU, respectively. The changes
in DEACT and KACT during CPB are shown in Figure 1.
Total blood loss and homologous red blood cell and blood
requirements were 487  387 g, 437  359 mL, and 673
 456 mL, respectively. In-hospital mortality was 0%.
Postoperative brain computed tomography demonstrated
neither deterioration nor a new occurrence of intracranial
hemorrhage in all patients.s during cardiopulmonary bypass (CPB).Gray zone represents target range
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Surgical TechniquesDISCUSSION
Nafamostat mesilate has been used as an anticoagulant in
substitution for heparin in the situations of CPB, left ventric-
ular assist devices, and hemodialysis. The main advantages
of nafamostat mesilate are its short half-life and its function-
ing to inactivate coagulation, fibrinolysis, and platelet
aggregation.Murase and colleagues8 demonstrated that nafa-
mostat mesilate inhibits fibrinolysis, preserves platelet func-
tion during CPB, and reduces blood loss. Ota and associates9
demonstrated successful CPBmanagement with mesilate for
3 patients with recent intracranial hemorrhage. Both groups
emphasized that inhibition of fibrinolysis activation was the
most important supplementary effect of nafamostat mesilate,
because as excessive fibrinolysis can cause intracranial
bleeding during and after CPB.8,9 On the other hand,
heparin enhances fibrinolytic activity during CPB, leading
to dissolution of clots and recurrence of bleeding. In this
study we demonstrated successful CPB management with
a continuous infusion of nafamostat mesilate in open heart
surgical procedures for patients after acute stroke.
Some authors have maintained that low-dose heparin
can achieve adequate anticoagulation during CPB, but Ov-
rum and coworkers2 reported that clot formation in the
cardiotomy reservoir occurred during CPB with low-
dose heparin. In our opinion, low-dose heparinization
during CPB should not be routinely used because of the
risk of clot formation; however, it provides an advantage
for patients with the risk of bleeding. We believe that
the combination of low-dose heparin and nafamostatFrom the Department of Cardiovascular Surgery, Himeji Cardiovascular Center,
Himeji, Japan.
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dose heparin.
Limitations to the current study include small sample
size, the lack of a control group, the lack of data on fibrino-
lysis, and the study’s retrospective nature. Further prospec-
tive analysis is needed to confirm the advantage of our CPB
strategy with low-dose heparin and nafamostat mesilate for
patients with bleeding risks.
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Interact Cardiovasc Thorac Surg. 2007;6:270-3.Transcatheter aortic valve implantation combined with conventional
heart surgery: Hybrid approach for complex cardiac pathologic
featuresMiralem Pasic, MD, PhD, Semih Buz, MD, Axel Unbehaun, MD, and Roland Hetzer, MD, PhD, Berlin,
GermanyA new hybrid approach, the combination of transcatheter
aortic valve implantation (TAVI) and conventional cardiacsurgery, might be a possible solution for patients considered
not suitable for complex conventional surgery. We have
summarized our preliminary experience.1-3
BRIEF CLINICAL REPORT
From April 2008 to October 2011, 11 patients underwent
simultaneous conventional cardiac surgery and TAVI with
or without additional percutaneous coronary intervention
(PCI) (Table 1). Ten patients had severe aortic valve steno-
sis, and one (patient 11) had pure insufficiency. The com-
bined procedure was the first heart operation in 6 patients,
the second in 3 patients, the third in 1 patient, and the fourth
in 1 patient.ery c September 2012
